NanoViricides, Inc. NEW (NNVC) News
Filter NNVC News Items
NNVC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NNVC News Highlights
- For NNVC, its 30 day story count is now at 2.
- Over the past 20 days, the trend for NNVC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NNVC are TALK.
Latest NNVC News From Around the Web
Below are the latest news stories about NANOVIRICIDES INC that investors may wish to consider to help them evaluate NNVC as an investment opportunity.
NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ETNanoViricides, Inc. (NYSE Amer. NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET. |
NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND StageNanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2022 with the Securities and Exchange Commission (SEC) on Monday, November 14, 2022. |
7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.Speculative penny stocks don't look as volatile now that volatility is unavoidable. |
This Company Is Looking For A Monkeypox Drug As City Investigates DeathsBy David Willey, Benzinga |
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND StageNanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission (SEC) on Thursday, October 13, 2022. |
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status RapidlyBy Rachael Green, Benzinga |
Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A SolutionBenzinga - Rachel Green |
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug StrategyNanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, provides further details on its rapid drug development strategy for Monkeypox virus. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning! |
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox VirusNanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus. |